The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
A Study on the Effect of Renal Function on the Pharmacakokinetics of RO5024048 (Parent of Prodrug RO5024048) Following Multiple Oral Dose Administration of RO5024048
Scientific title
The Effect of Renal Function on the Pharmacokinetics of RO4995855 (Parent of ProDrug RO5024048) Following Multiple Oral Dose Administration of RO5024048
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy Volunteer 0 0
Condition category
Condition code

Study type
Description of intervention(s) / exposure
Treatment: Drugs - RO5024048

Experimental: 1 - Normal Renal Function

Experimental: 2 - Mild Renal Impairment

Experimental: 3 - Moderate Renal Impairment

Treatment: Drugs: RO5024048
multiple oral doses for 5 days

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Phrmacokinetics of RO49958855 (parent molecule) and metabolites following multiple doses of RO5024048: AUC, Cmax, Tmax T1/2, Ae, Cl
Timepoint [1] 0 0
sampling days 1 and 3-11
Secondary outcome [1] 0 0
Effect of renal impairment on safety and tolerability: Adverse events, vital signs, ECG, laboratory parameters
Timepoint [1] 0 0
Throughout study, ECG and laboratory assessments days 3, 5, 6 and 17

Key inclusion criteria
- male or female adults, 18-75 years of age

- normal, or mildly or moderately impaired renal function (creatinine clearance >/= 30

- BMI 18-40 kg/m2

- stable renal function

- agree to abstain from alcohol consumption during study drug adminsitration and limit
consumption up to the end of the study

- agree to abstain from coffein consumption throughout study
Minimum age
18 Years
Maximum age
75 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
- positive urine or blood test for drugs of abuse not under a physician's prescription

- positive for HIV or HCV, or HBV with clinical symptoms or history of hepatitis

- uncontrolled hypertension

- renal transplant, dialysis patient, nephritic syndrome

- clinically significant cardiovascular, central nervous system, gastrointestinal or
liver disease or disorder

Study design
Purpose of the study
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Other design features
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Country [2] 0 0
United States of America
State/province [2] 0 0
Country [3] 0 0
New Zealand
State/province [3] 0 0

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Hoffmann-La Roche

Ethics approval
Ethics application status

Brief summary
This open-label, parallel group study will evaluate the effect of renal function on the
pharmacokinetics of RO4995855 following multiple oral dose administration of RO5024048 and
assess the effect of renal impairment on safety and tolerability of RO5024048. Adult males or
females with either normal renal function or mild or moderate renal impairment will receive
RO5024048 orally for 5 days. Target sample size is <50.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications